We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Medical Solutn | LSE:MLS | London | Ordinary Share | GB0009739649 | ORD 2P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.00 | 0.00% | 7.72 | 0.00 | 01:00:00 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMSBS
RNS Number : 4643Y
Source BioScience PLC
08 September 2015
8 September 2015
Source BioScience plc
(the 'Company')
Exercise of Share Options and Directors' Dealings
Source BioScience plc (LSE: SBS) announces that on 7 September it issued and allotted 3,878,854 new ordinary shares of 2 pence each in the Company (the 'New Ordinary Shares'), representing 1.11% of its enlarged issued share capital, following the net exercise of share options by certain Directors and other option holders under the Source BioScience plc Share Option Schemes at an effective net exercise price of nil.
As a result of the net exercise of share options:
-- Mr Laurence Turnbull, Chairman was allotted 2,041,667 New Ordinary Shares in full settlement of his 2007 share option awards which totalled 3,750,000 share options
-- Dr Nick Ash, Chief Executive Officer was allotted 1,454,243 New Ordinary Shares in full settlement of his 2006 and 2007 share option awards which totalled 2,500,000 share options
-- Dr Nick Leaves, Chief Operating Officer was allotted 265,152 New Ordinary Shares in full settlement of his 2007 share option awards which totalled 500,000 shares
The Company also announces that it was notified on 7 September 2015 that, following the exercise of share options, Mr Turnbull sold 2,041,667 Ordinary Shares; Dr Ash sold 1,454,243 Ordinary Shares and Dr Leaves sold 265,152 Ordinary Shares, all at 16.50p per Ordinary Share on 7 September 2015. Following the exercise of share options and the sale of Ordinary Shares, the number of Ordinary Shares held by each Director remains unchanged.
Application has been made for the New Ordinary Shares to be admitted to the Official List of the UK Listing Authority and to trading on the Main Market of the London Stock Exchange. It is expected that admission of the New Ordinary Shares will occur on or around 8 September 2015
Following the issue and allotment, the Company's issued share capital will comprise 349,100,255 ordinary shares of 2 pence each, which figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or change to their interest in, Source BioScience plc under the FSA's Disclosure and Transparency Rules. The New Ordinary Shares will rank pari passu with the existing Ordinary Shares and no Ordinary Shares are held in treasury.
This notification is provided in accordance with DTR3.1.4R(1).
--- ENDS ---
For further information, please contact:
Source BioScience plc
Dr Nick Ash, CEO and Company Secretary
Tel: +44 (0)115 973 9010
Email: enquiries@sourcebioscience.com
www.sourcebioscience.com
N+1 Singer (Financial Advisor, Sponsor and Broker)
Aubrey Powell/James White
Tel: +44 (0)207 496 3000
www.n1singer.com
About Source BioScience
Source BioScience plc (LSE: SBS) is a trusted provider of state of the art laboratory services and products to the healthcare and clinical, life and applied sciences and biopharma industries. It is an international business operating ten state of the art facilities in five countries and with customers in over 90 countries worldwide. The Group offers a complementary portfolio of laboratory services and products that share common technologies, laboratory processes, infrastructure and expertise. These include clinical diagnostics, genomics, proteomics, drug discovery and development research as well as controlled environment storage and testing services for a diverse range of markets. These services and products are provided to a large and diverse customer base including the top 50 pharmaceutical companies, leading universities and research institutes worldwide, the UK NHS and other healthcare providers. The Group is listed on the Premium Main Market of the London Stock Exchange.
This information is provided by RNS
The company news service from the London Stock Exchange
END
RDSSSMFWAFISEFU
(END) Dow Jones Newswires
September 08, 2015 13:20 ET (17:20 GMT)
1 Year Medical Solutions Chart |
1 Month Medical Solutions Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions